Skip to main content

Table 1 Clinical trials of ASI in suspected minimal residual CRC

From: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Ref ASI Stage of patient Overall Survival Disease-free Survival Follow up Jadad's grades
    No. of events/no. of subjects (year)  
[21] ATC Stage II Con:31 of 109 Con:35 of 109 7.6 B
    Exp:16 of 73 Exp:18 of 73   
   Stage III Con:26 of 44 Con:28 of 44   
    Exp:15of 33 Exp:15 of 33   
[22] ATC-BCG Stage II Con:21 of 77 Con:29 of 77 5 C
    Exp:14 of 80 Exp:17 of 80   
   Stage III Con:12 of 40 Con:17 of 40   
    Exp:16of 44 Exp:20 of 44   
[23] ATV-NDV Stage I-IV Con:16 of 25 NO 7 C
    Exp:12of 25    
[24] 17-1 Stage III Con:48 of 76 Con:54 of 76 7 B
  Antibody   Exp:39 of 90 Exp:50 of 90   
[25] ATC Stage I-IV Con:146 of 257 NO 7 C
    Exp:135 of 310    
[26] ATC Stage IV Con:48 of 50 NO 1 C
    Exp:20 of 42    
  1. Abbreviations: Ref, reference; ASI, active specific immunotherapy; Con, control group; Exp, ASI experiment group; ATC, antilogous tumor cells; NDV, newcastle disease virus; No, not done.